Drug Trial Radar · NCT07135986
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,602
Actual
Start
Sep 26, 2025
Primary completion
May 1, 2026
Study completion Sep 24, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Aug 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 3, modified double-blind, randomized, parallel-group, active-controlled, multicenter study with 2 arms and 4 groups to evaluate the immunogenicity and safety of MenACYW conjugate vaccine in children and adolescents versus control meningococcal vaccines licensed in China. Study details include: * The study duration will be approximately 180 days. * The vaccination visit will be Visit 1. * The visit frequency will be 2 on-site visits with a 30-day interval. A safety visit/telephone call is planned on the ninth day after the vaccination for all groups; a safety follow-up telephone call is planned for all groups 180 days post the last vaccination.
Conditions
- Meningococcal Infection
- Healthy Volunteers
Interventions
MenACYW conjugate vaccineBiological
Pharmaceutical form:Liquid solution-Route of administration:Intramuscular (IM) injection
MenACYW135 polysaccharide vaccineBiological
Pharmaceutical form: Lyophilized powder-Route of administration:IM injection
MenAC conjugate vaccineBiological
Pharmaceutical form:Lyophilized powder-Route of administration:IM injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants 7 through 17 years of age (Cohort I): Vaccine seroresponse to meningococcal serogroups A, C, Y, and WTime frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)
- Participants 7 through 17 years of age (Cohort I): Geometric mean titers (GMTs) of antibodies against meningococcal serogroups A, C, Y, and WTime frame: Day 31 (post- vaccination)
- Participants 7 through 17 years of age (Cohort I): Vaccine seroresponse to meningococcal serogroups W and Y will be assessed in participants receiving MenACYW conjugate vaccineTime frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)
- Participants 2 through 6 years of age (Cohort II): Vaccine seroresponse to meningococcal serogroups A and CTime frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)
- Participants 2 through 6 years of age (Cohort II): Geometric mean titers (GMTs) of antibodies against meningococcal serogroups A and CTime frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)
- Participants 2 through 6 years of age (Cohort II): Vaccine seroresponse to meningococcal serogroups W and Y in participants receiving MenACYW conjugate vaccineTime frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number : 1561001
Jingxi, China
Investigational Site Number : 1561003
Liuzhou, China
Investigational Site Number : 1561002
Tengzhou, China
Investigational Site Number : 1561000
Nanning, Guangxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.